Delayed US approval will hit Leo Pharma at full strength this year
Having first rejected eczema treatment tralokinumab, it took the US Food and Drug Administration eight additional months to approve the drug, a delay that had great consequences for developer Leo Pharma. Acting CEO Anders Kronborg says the FDA’s blow will begin to be felt for real this year.
by ULRICH QUISTGAARD, translated by daniel pedersen
Leo Pharma’s annual report published Thursday shows the repercussions from May of last year, when the US Food and Drug Administration decided not to grant the otherwise expected approval to atopic eczema drug tralokinumab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma disappoints as deficit surpasses USD 720m
For subscribers
